세계의 방사성 의약품 시장 : 규모, 점유율, 동향, 산업 분석 보고서 - 방사성 동위 원소 유형별, 용도별, 공급원별, 최종 사용자별, 지역별 예측(2025-2034년)

Radiopharmaceuticals Market Size, Share, Trends, & Industry Analysis Report By Radioisotope Type (Technetium-99, Fluorine-18), By Application, By Source, By End User, and By Region - Market Forecast, 2025-2034

US $ 4,250 ￦ 5,998,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 5,250 ￦ 7,410,000

PDF (Multi User License)

PDF 보고서를 동일 기업 20명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,250 ￦ 8,821,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

Polaris Market Research의 최신 조사에 따르면 세계의 방사성 의약품 시장 규모는 2034년까지 209억 4,000만 달러에 달할 전망입니다. 이 조사 보고서는 현재 시장 역학을 자세히 파악하고 향후 시장 성장에 대한 분석을 제공합니다.

방사성 의약품 시장은 병원과 영상 진단센터가 진단과 치료의 양면에서 핵 의학에 대한 의존도를 높이고 있기 때문에 꾸준히 성장하고 있습니다. 이 특수 화합물은 PET 및 SPECT와 같은 검사에 사용되며 병리학을 조기 및 정확하게 감지합니다.

현재 진행 중인 연구개발은 보다 정확하고 부작용이 적은 새로운 방사성 의약품의 개발을 진행하고 있습니다. 따라서 의료 서비스 제공업체는 최신 영상 진단 시스템에 투자하여 핵의학 부문을 확대하고 있습니다. 이 변화는 환자의 결과를 개선하고 고급 진단 및 치료 서비스를 제공합니다.

방사성 의약품 시장 보고서 하이라이트

방사성 동위 원소 유형별로는 뼈, 심장 및 종양 진단과 관련된 질병의 SPECT 이미징에 널리 적용되는 테크네튬-99 부문이 2024년 시장을 독점했습니다.

용도별로는 신경 분야가 2024년 시장을 독점했습니다. 이는 암 진단, 병기 분류, 치료 계획에 있어서 방사성 의약품의 채용이 확대되고 있기 때문입니다.

선원별로는 몰리브덴-99 등의 동위원소가 널리 사용되고 있기 때문에 원자로 분야가 2024년 시장을 독점했습니다.

2024년 세계 방사성 의약품 시장에서는 핵의학 인프라 정비가 진행되고 있는 북미가 대부분의 점유율을 차지하고 있습니다.

아시아태평양은 인도, 중국, 한국의 건강 관리 인프라의 급속한 성장으로 상당한 시장 점유율을 차지할 것으로 예상됩니다.

세계 주요 시장 기업은 Advanced Accelerator Applications SA, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bracco Imaging S.p.A., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler SE, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., GlaxoSmithKline plc (GSK plc), Jubilant Radiopharma Limited, Lantheus Holdings, Inc., Eli Lilly and Company, Mallinckrodt plc 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 방사성 의약품 시장 인사이트

• 시장 현황
• 방사성의약품 시장 역학
  • 성장 촉진요인과 기회
    • 세계적으로 암과 심혈관 질환이 증가
    • 세계 인구의 고령화
  • 억제요인과 과제
    • 높은 생산 비용과 복잡한 규제 승인
• PESTEL 분석
• 방사성 의약품 시장 동향
• 밸류체인 분석

제5장 세계의 방사성 의약품 시장 : 방사성 동위 원소 유형별

• 주요 조사 결과
• 소개
• 테크네튬 99
• 불소 18
• 요오드 131
• 루테튬 177
• 이트륨 90
• 갈륨 68
• 갈륨 67
• 루비듐 82
• 요오드 123
• 요오드 125
• 인듐 111
• 기타

제6장 세계의 방사성 의약품 시장 : 용도별

• 주요 조사 결과
• 소개
• 종양학
• 심장병학
• 소화기내과
• 신경내분비학
• 신경학
• 신장학
• 기타

제7장 세계의 방사성 의약품 시장 : 공급원별 전망

• 주요 조사 결과
• 소개
• 원자로
• 사이클로트론

제8장 세계의 방사성 의약품 시장 : 최종 사용자별

• 주요 조사 결과
• 소개
• 병원
• 진단센터
• 암 연구 기관
• 외래수술센터(ASC)
• 기타

제9장 세계의 방사성 의약품 시장 : 지역별

• 주요 조사 결과
• 소개
  • 방사성 의약품 시장 평가 : 지역별, 2020-2034년
• 북미
  • 북미 : 방사성 동위 원소 유형별, 2020-2034년
  • 북미 : 용도별, 2020-2034년
  • 북미 : 공급원별 전망, 2020-2034년
  • 북미 : 최종사용자별, 2020-2034년
  • 미국
  • 캐나다
• 유럽
  • 유럽 : 방사성 동위 원소 유형별, 2020-2034년
  • 유럽 : 용도별, 2020-2034년
  • 유럽 : 공급원별 전망, 2020-2034년
  • 유럽 : 최종사용자별, 2020-2034년
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 스페인
  • 네덜란드
  • 러시아
  • 기타 유럽
• 아시아태평양
  • 아시아태평양 : 방사성 동위 원소 유형별, 2020-2034년
  • 아시아태평양 : 용도별, 2020-2034년
  • 아시아태평양 : 공급원별 전망, 2020-2034년
  • 아시아태평양 : 최종 사용자별, 2020-2034년
  • 중국
  • 인도
  • 말레이시아
  • 일본
  • 인도네시아
  • 한국
  • 호주
  • 기타 아시아태평양
• 중동 및 아프리카
  • 중동 및 아프리카 : 방사성 동위 원소 유형별, 2020-2034년
  • 중동 및 아프리카 : 용도별, 2020-2034년
  • 중동 및 아프리카 : 공급원별 전망, 2020-2034년
  • 중동 및 아프리카 : 최종사용자별, 2020-2034년
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 이스라엘
  • 남아프리카
  • 기타 중동 및 아프리카
• 라틴아메리카
  • 라틴아메리카 : 방사성 동위 원소 유형별, 2020-2034년
  • 라틴아메리카 : 용도별, 2020-2034년
  • 라틴아메리카 : 공급원별 전망, 2020-2034년
  • 라틴아메리카 : 최종사용자별, 2020-2034년
  • 멕시코
  • 브라질
  • 아르헨티나
  • 기타 라틴아메리카

제10장 경쟁 구도

• 확대 및 인수 분석
  • 확대
  • 인수
• 제휴/협업/합의/공개

제11장 기업 프로파일

• Advanced Accelerator Applications SA
• AstraZeneca plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bracco Imaging SpA
• Cardinal Health, Inc.
• Curium Pharma
• Eckert & Ziegler SE
• F. Hoffmann-La Roche Ltd
• GE HealthCare Technologies Inc.
• GlaxoSmithKline plc(GSK plc)
• Jubilant Radiopharma Limited

JHS

영문 목차

영문목차

The radiopharmaceuticals market size is expected to reach USD 20.94 Billion by 2034, according to a new study by Polaris Market Research. The report "Radiopharmaceuticals Market Size, Share, Trends, & Industry Analysis Report By Radioisotope Type (Technetium-99, Fluorine-18), By Application, By Source, By End User, and By Region - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The radiopharmaceuticals market is growing steadily as hospitals and imaging centers increasingly rely on nuclear medicine for both diagnosis and treatment. These specialized compounds are used in scans such as PET and SPECT to detect conditions early and accurately.

Ongoing research is leading to the development of new radiopharmaceuticals that are more precise and contains fewer side effects. Therefore, healthcare providers are investing in modern imaging systems and expanding nuclear medicine departments. This shift is improving patient outcomes, providing advanced diagnostic and therapeutic services.

Radiopharmaceuticals Market Report Highlights

Based on radioisotope type, the technetium-99 segment dominated the market in 2024, due to its widespread application in SPECT imaging for conditions related to bone, cardiac, and oncology diagnostics.

In terms of application, the neurology segment dominated the market in 2024. This is owing the growing adoption of radiopharmaceuticals in cancer diagnosis, staging, and treatment planning.

In terms of source, the nuclear reactors segment dominated the market in 2024, due to the extensive use of isotopes such as molybdenum-99.

North America accounted for the majority share in the global Radiopharmaceuticals market in 2024, due to advanced nuclear medicine infrastructure.

Asia Pacific held substantial market share, owing to rapid growth in healthcare infrastructure across India, China, and South Korea.

A few global key market players include Advanced Accelerator Applications SA, AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bracco Imaging S.p.A., Cardinal Health, Inc., Curium Pharma, Eckert & Ziegler SE, F. Hoffmann-La Roche Ltd, GE HealthCare Technologies Inc., GlaxoSmithKline plc (GSK plc), Jubilant Radiopharma Limited, Lantheus Holdings, Inc., Eli Lilly and Company, and Mallinckrodt plc.

Polaris Market Research has segmented the market report on the basis of type, application, source, end user, and region:

By Radioisotope Type Outlook (Revenue, USD Billion, 2020-2034)

Technetium-99

Fluorine-18

Iodine-131

Lutetium-177

Yttrium-90

Gallium-68

Gallium-67

Rubidium-82

Iodine-123

Iodine-125

Indium-111

Others

By Application Outlook (Revenue, USD Billion, 2020-2034)

Oncology

Cardiology

Gastroenterology

Neuroendocrinology

Neurology

Nephrology

Others

By Source Outlook (Revenue, USD Billion, 2020-2034)

Nuclear Reactors

Cyclotrons

By End User Outlook (Revenue, USD Billion, 2020-2034)

Hospitals

Diagnostic Centers

Cancer Research Institutes

Ambulatory Surgical Centers

Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

North America

US

Canada

Europe

Germany

France

UK

Italy

Spain

Netherlands

Russia

Rest of Europe

Asia Pacific

China

Japan

India

Malaysia

South Korea

Indonesia

Australia

Vietnam

Rest of Asia Pacific

Middle East & Africa

Saudi Arabia

UAE

Israel

South Africa

Rest of Middle East & Africa

Latin America

Mexico

Brazil

Argentina

Rest of Latin America

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Radiopharmaceuticals Market Insights

• 4.1. Radiopharmaceuticals Market - Market Snapshot
• 4.2. Radiopharmaceuticals Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Rising Number of Cancer and Cardiovascular Diseases Globally
    • 4.2.1.2. Aging Global Population
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High Production Costs and Complex Regulatory Approvals
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTEL Analysis
• 4.5. Radiopharmaceuticals Market Trends
• 4.6. Value Chain Analysis

5. Global Radiopharmaceuticals Market, by Radioisotope Type

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
• 5.3. Technetium-99
  • 5.3.1. Global Radiopharmaceuticals Market, by Technetium-99, by Region, 2020-2034 (USD Billion)
• 5.4. Fluorine-18
  • 5.4.1. Global Radiopharmaceuticals Market, by Fluorine-18, by Region, 2020-2034 (USD Billion)
• 5.5. Iodine-131
  • 5.5.1. Global Radiopharmaceuticals Market, by Iodine-131, by Region, 2020-2034 (USD Billion)
• 5.6. Lutetium-177
  • 5.6.1. Global Radiopharmaceuticals Market, by Lutetium-177, by Region, 2020-2034 (USD Billion)
• 5.7. Yttrium-90
  • 5.7.1. Global Radiopharmaceuticals Market, by Yttrium-90, by Region, 2020-2034 (USD Billion)
• 5.8. Gallium-68
  • 5.8.1. Global Radiopharmaceuticals Market, by Gallium-68, by Region, 2020-2034 (USD Billion)
• 5.9. Gallium-67
  • 5.9.1. Global Radiopharmaceuticals Market, by Gallium-67, by Region, 2020-2034 (USD Billion)
• 5.10. Rubidium-82
  • 5.10.1. Global Radiopharmaceuticals Market, by Rubidium-82, by Region, 2020-2034 (USD Billion)
• 5.11. Iodine-123
  • 5.11.1. Global Radiopharmaceuticals Market, by Iodine-123, by Region, 2020-2034 (USD Billion)
• 5.12. Iodine-125
  • 5.12.1. Global Radiopharmaceuticals Market, by Iodine-125, by Region, 2020-2034 (USD Billion)
• 5.13. Indium-111
  • 5.13.1. Global Radiopharmaceuticals Market, by Indium-111, by Region, 2020-2034 (USD Billion)
• 5.14. Others
  • 5.14.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

6. Global Radiopharmaceuticals Market, by Application

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
• 6.3. Oncology
  • 6.3.1. Global Radiopharmaceuticals Market, by Oncology, by Region, 2020-2034 (USD Billion)
• 6.4. Cardiology
  • 6.4.1. Global Radiopharmaceuticals Market, by Cardiology, by Region, 2020-2034 (USD Billion)
• 6.5. Gastroenterology
  • 6.5.1. Global Radiopharmaceuticals Market, by Gastroenterology, by Region, 2020-2034 (USD Billion)
• 6.6. Neuroendocrinology
  • 6.6.1. Global Radiopharmaceuticals Market, by Neuroendocrinology, by Region, 2020-2034 (USD Billion)
• 6.7. Neurology
  • 6.7.1. Global Radiopharmaceuticals Market, by Neurology, by Region, 2020-2034 (USD Billion)
• 6.8. Nephrology
  • 6.8.1. Global Radiopharmaceuticals Market, by Nephrology, by Region, 2020-2034 (USD Billion)
• 6.9. Others
  • 6.9.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Radiopharmaceuticals Market, by Source Outlook

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
• 7.3. Nuclear Reactors
  • 7.3.1. Global Radiopharmaceuticals Market, by Nuclear Reactors, by Region, 2020-2034 (USD Billion)
• 7.4. Cyclotrons
  • 7.4.1. Global Radiopharmaceuticals Market, by Cyclotrons, by Region, 2020-2034 (USD Billion)

8. Global Radiopharmaceuticals Market, by End User

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
• 8.3. Hospitals
  • 8.3.1. Global Radiopharmaceuticals Market, by Hospitals, by Region, 2020-2034 (USD Billion)
• 8.4. Diagnostic Centers
  • 8.4.1. Global Radiopharmaceuticals Market, by Diagnostic Centers, by Region, 2020-2034 (USD Billion)
• 8.5. Cancer Research Institutes
  • 8.5.1. Global Radiopharmaceuticals Market, by Cancer Research Institutes, by Region, 2020-2034 (USD Billion)
• 8.6. Ambulatory Surgical Centers
  • 8.6.1. Global Radiopharmaceuticals Market, by Ambulatory Surgical Centers, by Region, 2020-2034 (USD Billion)
• 8.7. Others
  • 8.7.1. Global Radiopharmaceuticals Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Radiopharmaceuticals Market, by Geography

• 9.1. Key Findings
• 9.2. Introduction
  • 9.2.1. Radiopharmaceuticals Market Assessment, By Geography, 2020-2034 (USD Billion)
• 9.3. Radiopharmaceuticals Market - North America
  • 9.3.1. North America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 9.3.2. North America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 9.3.3. North America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 9.3.4. North America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.3.5. Radiopharmaceuticals Market - U.S.
    • 9.3.5.1. U.S.: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.3.5.2. U.S.: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.3.5.3. U.S.: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.3.5.4. U.S.: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.3.6. Radiopharmaceuticals Market - Canada
    • 9.3.6.1. Canada: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.3.6.2. Canada: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.3.6.3. Canada: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.3.6.4. Canada: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
• 9.4. Radiopharmaceuticals Market - Europe
  • 9.4.1. Europe: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 9.4.2. Europe: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 9.4.3. Europe: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 9.4.4. Europe: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.5. Radiopharmaceuticals Market - UK
    • 9.4.5.1. UK: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.5.2. UK: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.5.3. UK: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.5.4. UK: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.6. Radiopharmaceuticals Market - France
    • 9.4.6.1. France: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.6.2. France: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.6.3. France: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.6.4. France: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.7. Radiopharmaceuticals Market - Germany
    • 9.4.7.1. Germany: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.7.2. Germany: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.7.3. Germany: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.7.4. Germany: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.8. Radiopharmaceuticals Market - Italy
    • 9.4.8.1. Italy: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.8.2. Italy: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.8.3. Italy: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.8.4. Italy: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.9. Radiopharmaceuticals Market - Spain
    • 9.4.9.1. Spain: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.9.2. Spain: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.9.3. Spain: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.9.4. Spain: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.10. Radiopharmaceuticals Market - Netherlands
    • 9.4.10.1. Netherlands: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.10.2. Netherlands: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.10.3. Netherlands: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.10.4. Netherlands: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.11. Radiopharmaceuticals Market - Russia
    • 9.4.11.1. Russia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.11.2. Russia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.11.3. Russia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.11.4. Russia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.4.12. Radiopharmaceuticals Market - Rest of Europe
    • 9.4.12.1. Rest of Europe: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.4.12.2. Rest of Europe: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.4.12.3. Rest of Europe: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.4.12.4. Rest of Europe: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
• 9.5. Radiopharmaceuticals Market - Asia Pacific
  • 9.5.1. Asia Pacific: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 9.5.2. Asia Pacific: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 9.5.3. Asia Pacific: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 9.5.4. Asia Pacific: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.5. Radiopharmaceuticals Market - China
    • 9.5.5.1. China: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.5.2. China: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.5.3. China: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.5.4. China: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.6. Radiopharmaceuticals Market - India
    • 9.5.6.1. India: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.6.2. India: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.6.3. India: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.6.4. India: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.7. Radiopharmaceuticals Market - Malaysia
    • 9.5.7.1. Malaysia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.7.2. Malaysia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.7.3. Malaysia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.7.4. Malaysia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.8. Radiopharmaceuticals Market - Japan
    • 9.5.8.1. Japan: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.8.2. Japan: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.8.3. Japan: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.8.4. Japan: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.9. Radiopharmaceuticals Market - Indonesia
    • 9.5.9.1. Indonesia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.9.2. Indonesia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.9.3. Indonesia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.9.4. Indonesia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.10. Radiopharmaceuticals Market - South Korea
    • 9.5.10.1. South Korea: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.10.2. South Korea: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.10.3. South Korea: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.10.4. South Korea: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.11. Radiopharmaceuticals Market - Australia
    • 9.5.11.1. Australia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.11.2. Australia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.11.3. Australia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.11.4. Australia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.5.12. Radiopharmaceuticals Market - Rest of Asia Pacific
    • 9.5.12.1. Rest of Asia Pacific: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.5.12.2. Rest of Asia Pacific: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.5.12.3. Rest of Asia Pacific: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.5.12.4. Rest of Asia Pacific: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
• 9.6. Radiopharmaceuticals Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 9.6.2. Middle East & Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 9.6.3. Middle East & Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 9.6.4. Middle East & Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6.5. Radiopharmaceuticals Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6.6. Radiopharmaceuticals Market - UAE
    • 9.6.6.1. UAE: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.6.2. UAE: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.6.3. UAE: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.6.4. UAE: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6.7. Radiopharmaceuticals Market - Israel
    • 9.6.7.1. Israel: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.7.2. Israel: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.7.3. Israel: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.7.4. Israel: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6.8. Radiopharmaceuticals Market - South Africa
    • 9.6.8.1. South Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.8.2. South Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.8.3. South Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.8.4. South Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.6.9. Radiopharmaceuticals Market - Rest of Middle East & Africa
    • 9.6.9.1. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.6.9.2. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.6.9.3. Rest of Middle East & Africa: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.6.9.4. Rest of Middle East & Africa: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
• 9.7. Radiopharmaceuticals Market - Latin America
  • 9.7.1. Latin America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
  • 9.7.2. Latin America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
  • 9.7.3. Latin America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
  • 9.7.4. Latin America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.7.5. Radiopharmaceuticals Market - Mexico
    • 9.7.5.1. Mexico: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.7.5.2. Mexico: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.7.5.3. Mexico: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.7.5.4. Mexico: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.7.6. Radiopharmaceuticals Market - Brazil
    • 9.7.6.1. Brazil: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.7.6.2. Brazil: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.7.6.3. Brazil: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.7.6.4. Brazil: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.7.7. Radiopharmaceuticals Market - Argentina
    • 9.7.7.1. Argentina: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.7.7.2. Argentina: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.7.7.3. Argentina: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.7.7.4. Argentina: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)
  • 9.7.8. Radiopharmaceuticals Market - Rest of Latin America
    • 9.7.8.1. Rest of Latin America: Radiopharmaceuticals Market, by Radioisotope Type, 2020-2034 (USD Billion)
    • 9.7.8.2. Rest of Latin America: Radiopharmaceuticals Market, by Application, 2020-2034 (USD Billion)
    • 9.7.8.3. Rest of Latin America: Radiopharmaceuticals Market, by Source Outlook, 2020-2034 (USD Billion)
    • 9.7.8.4. Rest of Latin America: Radiopharmaceuticals Market, by End User, 2020-2034 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Advanced Accelerator Applications SA
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. AstraZeneca plc
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. Bayer AG
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Boehringer Ingelheim International GmbH
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Bracco Imaging S.p.A.
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. Cardinal Health, Inc.
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. Curium Pharma
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Eckert & Ziegler SE
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. F. Hoffmann-La Roche Ltd
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. GE HealthCare Technologies Inc.
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. GlaxoSmithKline plc (GSK plc)
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Jubilant Radiopharma Limited
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development

관련자료